US2022017631A1PendingUtilityA1

Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma

60
Assignee: ENGMAB SARLPriority: Nov 2, 2016Filed: Jun 24, 2021Published: Jan 20, 2022
Est. expiryNov 2, 2036(~10.3 yrs left)· nominal 20-yr term from priority
Inventors:Minh Diem VuKlaus StreinBruno David Lourenco PaivaJesus Fernado San Miguel Izquierdo
C07K 2317/33C07K 2317/64A61P 35/00A61K 2039/505C07K 16/2878C07K 16/2809C07K 2317/31C07K 16/2896C07K 16/468A61K 31/454C07K 2317/73C07K 2317/92A61P 7/00A61K 39/3955A61P 35/02A61P 43/00C07K 16/2818
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3ε (CD3) together with an immunotherapeutic drug for combined use in treating multiple myeloma.

Claims

exact text as granted — not AI-modified
1 .- 10 . (canceled) 
     
     
         11 . A method of treating multiple myeloma comprising administering to a patient in need of such treatment a therapeutically effective amount of
 a) a bispecific antibody comprising a first binding part specifically binding to human B cell maturation antigen (BCMA) and a second binding part specifically binding to human CDR (CD3), wherein said first binding part comprises: a VH region comprising a CDR1H region of SEQ ID NO:21, a CDR2H region of SEQ ID NO:22 and a CDR3H region of SEQ ID NO:17 and a VL region comprising a CDR1L region of SEQ ID NO:27, a CDR2L region of SEQ ID NO:28 and a CDR3L region of SEQ ID NO:20; and,   b) an immunotherapeutic drug selected from the group consisting of thalidomide or an immunotherapeutic derivative thereof, an anti-CD38 antibody, an anti-PD-1 antibody and an anti-PD-L1 antibody;   
       wherein the bispecific antibody and the immunotherapeutic drug are administered separately or together. 
     
     
         12 . The method according to  claim 11  wherein the immunotherapeutic drug is selected from the group consisting of daratumumab, isatuximab, MOR202, Ab79, Ab19, thalidomide, lenalidomide, pomalidomide, CC-122, CC-220, pembrolizumab, pidilizumab, nivolumab, MEDI-0680, PDR001, REGN2810, lambrolizumab, MDX-1106, BGB-108, h409A11, h409A16, h409A17, atezolizumab, avelumab, durvalumab, and MDX-1105. 
     
     
         13 . The method according to  claim 12  wherein the immunotherapeutic drug is daratumumab. 
     
     
         14 . The method according to  claim 12  wherein the immunotherapeutic drug is isatuximab. 
     
     
         15 . The method according to  claim 12  wherein the immunotherapeutic drug is MOR202. 
     
     
         16 . The method according to  claim 12  wherein the immunotherapeutic drug is Ab79. 
     
     
         17 . The method according to  claim 12  wherein the immunotherapeutic drug is Ab19. 
     
     
         18 . The method according to  claim 12  wherein the immunotherapeutic drug is thalidomide. 
     
     
         19 . The method according to  claim 12  wherein the immunotherapeutic drug is lenalidomide. 
     
     
         20 . The method according to  claim 12  wherein the immunotherapeutic drug is pomalidomide. 
     
     
         21 . The method according to  claim 12  wherein the immunotherapeutic drug is CC-122. 
     
     
         22 . The method according to  claim 12  wherein the immunotherapeutic drug is CC-220. 
     
     
         23 . The method according to  claim 12  wherein the immunotherapeutic drug is pembrolizumab. 
     
     
         24 . The method according to  claim 12  wherein the immunotherapeutic drug is pidilizumab. 
     
     
         25 . The method according to  claim 12  wherein the immunotherapeutic drug is nivolumab. 
     
     
         26 . The method according to  claim 12  wherein the immunotherapeutic drug is MEDI-0680. 
     
     
         27 . The method according to  claim 12  wherein the immunotherapeutic drug is PDR001. 
     
     
         28 . The method according to  claim 12  wherein the immunotherapeutic drug is REGN2810. 
     
     
         29 . The method according to  claim 12  wherein the immunotherapeutic drug is lambrolizumab. 
     
     
         30 . The method according to  claim 12  wherein the immunotherapeutic drug is MDX-1106. 
     
     
         31 . The method according to  claim 12  wherein the immunotherapeutic drug is BGB-108. 
     
     
         32 . The method according to  claim 12  wherein the immunotherapeutic drug is h409A11. 
     
     
         33 . The method according to  claim 12  wherein the immunotherapeutic drug is h409A16. 
     
     
         34 . The method according to  claim 12  wherein the immunotherapeutic drug is h409A17. 
     
     
         35 . The method according to  claim 12  wherein the immunotherapeutic drug is atezolizumab. 
     
     
         36 . The method according to  claim 12  wherein the immunotherapeutic drug is avelumab. 
     
     
         37 . The method according to  claim 12  wherein the immunotherapeutic drug is durvalumab. 
     
     
         38 . The method according to  claim 12  wherein the immunotherapeutic drug is MDX-1105.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.